Information for Participants
The MAMA study is designed to find out whether it is better for women who are pregnant with inflammatory arthritis to stop or to continue taking biologic medications.
It is not a straightforward decision when it comes to stopping or continuing biologic medications in the second half of pregnancy. We don't know the impact of stopping or continuing biologics on how well a person's arthritis is controlled in pregnancy or in the postnatal period (after the baby is born). The MAMA study is looking to answer this question.
How will we do this?
Women who take part in the MAMA Trial will be allocated at random to one of the following groups:
The continuing group. Women in this group will continue taking their biologic thoughout pregnancy.
OR
The stopping group. Women in this group will stop their biologics before the third trimester (28 weeks) of pregnancy, and restart no earlier that 2 weeks post-pregnancy.
Other than stopping or continuing your current biologic by 28 weeks gestation no other changes will be made to your arthritis treatment as a result of being in this study.
Both continuing and stopping using biologics beyond 28 weeks of pregnancy are routine practice in the UK.
Who can take part in the trial
Pregnant women less than 28 completed weeks of gestation prescribed a biologic for Autoimmune Inflammatory Arthritis and meet the eligibility criteria for the MAMA trial.
